Research programme: Helicobacter pylori infection therapies - AstraZeneca
Latest Information Update: 03 Sep 2010
At a glance
- Originator AstraZeneca
- Class Pyrazoles; Small molecules
- Mechanism of Action Glutamate racemase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Helicobacter infections